Celularity (CELU)

The company is best known for its focus on allogeneic cell therapies, meaning treatments designed to be manufactured from donor-derived cells rather than produced individually from each patient. This approach is intended to support scalable, off-the-shelf therapeutic products if clinical and regulatory development is successful. Celularity’s research has included placental-derived natural killer cells, T cells, mesenchymal-like adherent stromal cells, and related cellular platforms.

Celularity also operates businesses outside early-stage drug development. Its activities are organized into three main segments: Cell Therapy, Degenerative Disease, and BioBanking. The Degenerative Disease segment accounts for the majority of revenue and includes biomaterial products derived from placental tissue that are used in areas such as wound care, surgical applications, and tissue repair. The BioBanking segment reflects services tied to the collection and storage of biological materials.

As a public life sciences company, Celularity combines a commercial biomaterials business with higher-risk clinical development programs. Its investment profile depends on product sales in existing markets, progress in cell therapy research, manufacturing execution, regulatory reviews, and the company’s ability to fund development. Its distinctive feature is the attempt to build a broad regenerative medicine platform around placental-derived cells and tissues.